RecruitingPhase 4NCT05059626

Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee

Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Women With Endometriosis


Sponsor

Penn State University

Enrollment

28 participants

Start Date

Dec 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis. Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovascular function including endothelium-dependent vasodilation.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bazedoxifene 20/Estrogens,Con 0.45Mg Tb and a drug called simvastatin 10mg for people with endometriosis. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGsimvastatin 10mg

Simvastation acts as a systemic LOX inhibitor.

DRUGBazedoxifene 20/Estrogens,Con 0.45Mg Tb

Duavee is a selective estrogen receptor modulator.


Locations(1)

The John B. Pierce Laboratory

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05059626


Related Trials